Volume 31, Number 8—August 2025
CME ACTIVITY - Research
Scheffersomyces spartinae Fungemia among Pediatric Patients, Pakistan, 2020–2024
Table 2
MICs of 108 isolates from Scheffersomyces spartinae fungemia among pediatric patients, Pakistan, 2020–2024*
Antifungal drug | MIC, µg/mL |
||
---|---|---|---|
Detected range | MIC50 | MIC90 | |
Fluconazole | 0.06–16 | 0.5 | 1 |
Itraconazole | 0.015–2 | 0.06 | 0.12 |
Voriconazole | 0.008–1 | 0.03 | 0.03 |
Posaconazole | 0.008–1 | 0.03 | 0.06 |
Flucytosine | 0.06–64 | 32 | 64 |
Amphotericin | 0.03–0.5 | 0.12 | 0.25 |
Caspofungin | 0.015–0.5 | 0.06 | 0.12 |
Anidulafungin | 0.015–0.5 | 0.12 | 0.12 |
Micafungin | 0.015–0.25 | 0.06 | 0.12 |
*MIC50, concentration required to inhibit 50% of strains; MIC90, concentration required to inhibit 90% of strains.
Page created: June 02, 2025
Page updated: July 24, 2025
Page reviewed: July 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.